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ABSTRACT
Introduction: Fractional exhaled nitric oxide
(FeNO) is a non-invasive marker of airway
inflammation, and a new portable analyzer
(NIOX VERO) is now available. Our studies
aimed to assess the agreement of measurements
between NIOX VERO and a reference device
(NIOX MINO) and assess the reproducibility of
NIOX VERO.
Methods: Paired FeNO readings were obtained
from 112 subjects from both devices to assess
agreement and reproducibility. FeNO readings
were obtained from 122 subjects using NIOX
VERO to assess inter-operator repeatability. All
subjects had a diagnosis of asthma and were
aged C7 years.
Results: Agreement was shown with 90.8% of
subjects within tolerance limits for the first
valid FeNO measurement. Mean observed
paired difference for the first valid FeNO mea-
surement on each device was -4.6 ppb [95%
confidence interval (CI) -5.825 to -3.377;
p\0.0001]. Weighted Deming Regression
Analysis showed a slope of 0.842 (95% CI 0.757,
0.927) and a y-intercept of -0.472 (95% CI
-1.999, 1.055). Paired differences were centered
close to 0. Intra-subject repeatability of NIOX
VERO was significantly better than NIOX
MINO (p = 0.0112). Further, inter-operator
repeatability was achieved with NIOX VERO
with a mean intra-subject variance of
6.61 ± 17.954 ppb (upper 95% CI 9.41) and an
estimated standard deviation of 2.57 (upper
95% CI 3.07). The coefficient of variance was
0.066 ± 0.054 (upper 95% CI 0.074).
Conclusion: Our findings show that the
portable instrument NIOX VERO is clinically
equivalent to NIOX MINO when used in an
asthma population. The NIOX VERO analyzer
gives reproducible, consistentmeasurements that
are well within the technical specifications of the
device, showing no observable pattern of a train-
ing effect oroperator-order effect on FeNOresults.
Thus, our findings validate the NIOX VERO.
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INTRODUCTION
Exhaled nitric oxide (NO) originates primarily
in bronchial epithelial cells. NO is an excellent
surrogate marker of inhaled corticosteroid
(ICS)-sensitive local type-2 cytokine-driven
inflammatory mechanisms, which are of central
importance in allergic airway inflammation
[1–4].
The detection of NO in exhaled air was first
reported in 1991 [5], and was later shown to be
elevated in exhaled air from patients with
asthma [6]. Measuring the fraction of exhaled
NO (FeNO) offers the only simple, non-invasive
and objective method of assessing local airway
inflammation in asthma [1, 7, 8]. FeNO is now
an established biomarker for airway inflamma-
tion and is strongly recommended by the
American Thoracic Society (ATS) for the diag-
nosis and management of asthma [9].
FeNO is easily measured in a clinical setting
using handheld or stationary analyzers [10]. The
ideal analyzer is portable and easy to use with
good reproducibility and reliability regardless of
patient baseline FeNO, age, or operator exper-
tise [11]. NIOX VERO and NIOX MINO are
two such handheld electrochemical analyzers,
which enable rapid and cost-effective assess-
ment of airway inflammation in asthma at the
point of care. Furthermore, the testing is easy to
perform and requires minimal training for the
operator to use. The assessment cannot be
influenced by patient effort or variations in the
clinician’s technique. NIOX MINO and NIOX
VERO do not require calibration at the clinic,
while built-in controls and external quality
control procedures warrant reliability of mea-
sured values. Both devices can be used by
patients aged 4 years and older in the European
Union (EU) and patients aged 7 years and older
in the United States (US). NIOX VERO con-
tains significant improvements learned from
years of making and using electrochemical
sensors for the measurement of exhaled nitric
oxide. When compared with NIOX MINO,
enhancements to NIOX VERO include its use
without being connected to a power supply and
improved visibility of the display screen. In
addition, NIOX VERO has an ergonomic han-
dle to aid portability.
In this paper, we describe the outcomes of
four studies performed to validate the NIOX
VERO analyzer.
METHODS
Agreement between NIOX MINO and NIOX
VERO was investigated in two studies, AER-045
and AER-048 (AER-045/048). Repeatability of
FeNO measured with NIOX VERO using dif-
ferent operators was also evaluated across two
studies, TV-014 and TV-018 (TV-014/018).
AER-045 and AER-048 share the same method-
ology, as do TV-014 and TV-018 with the
exception that AER-048 and TV-018 also aimed
to enrol a proportion of patients with higher
FeNO ([40 ppb). Since the second studies are
extensions of the first two, only the pooled data
from each pair of studies are presented in this
article.
The studies were approved by the local
Institutional Review Board and were conducted
in compliance with Good Clinical Practice and
the Declaration of Helsinki. All subjects pro-
vided written consent, or legal guardians pro-
vided written assent, prior to any study
procedures being performed. In each study,
subjects attended the clinic once for
study-specific assessments.
Study Design
AER-045/048 were multi-center, open-label,
randomized, single-visit, controlled studies to
compare FeNO measured with NIOX VERO
and NIOX MINO. TV-014/018 comprised
multi-center, randomized, single-visit, point-
of-care studies to assess inter-operator variabil-





Males and females were enrolled aged 7 years or
over with physician-diagnosed asthma [or were
under evaluation for asthma (AER-045)] and
able to perform FeNO measurements using the
study analyzer(s). Subjects who did not refrain
from taking food, drink, nicotine or strenuous
exercise within 1 h of the FeNO assessments or
who had any other pulmonary disease or acute
respiratory illness or sinusitis were excluded. For
AER-045, subjects were excluded with severely
impaired lung function (predicted FEV1\50%),
diagnosed lung cancer or other active pul-
monary infectious disease, including
tuberculosis.
For AER-048 only, subjects were included if
they had risk factors for elevated FeNO
([50 ppb) or they had current respiratory
symptoms such as cough, wheeze, and/or dys-
pnea or a history of non-compliance with pre-
scribed asthma treatment. In addition, subjects
were only included in the AER-048 if they had a
FeNO of[40 ppb on the study day.
Operators
Operators were male and female physicians,
nurses, respiratory therapists or laboratory
technicians already familiar with NIOX MINO
(TV-014/018).
Devices
NIOX VERO (Aerocrine, Sweden) was under
development at the time of the study in the US
and was subsequently cleared by the FDA in
November 2014. The analyzer was used
according to the Investigator User Manual [12].
NIOX MINO (Aerocrine) is CE marked and
cleared for clinical use in the US by the FDA,
and was used according to the User Manual [13].
Assessments
In all studies, FeNO measurements were
obtained using a standard technique—single
breath online, 10-s exhalation in accordance
with current recommendations [14]. If a valid
FeNO assessment was not achieved after 10 at-
tempts, the measurement was considered
unsuccessful and the subject was discharged
from the study. Data from all valid FeNO mea-
surements for all subjects were analyzed. In
AER-045/048, subjects attempted a total of two
valid exhalations (maximum of six exhalations)
at a fixed flow rate (50 mL/s) with each device.
The order in which the devices were used was
randomized. An evaluable subject successfully
completed four valid FeNO measurements, two
with each device, within approximately 30 min.
Adverse events (AEs) and serious injuries
were assessed from the time of informed con-
sent/assent and during the study visit for each
subject (not for operators). Further details are
provided in the online supplement.
Statistical Methods
Statistical Analyses
Two-sided tests were used for all analyses; 95%
confidence intervals (CI) were calculated and a
p value B0.05 was considered statistically sig-
nificant. Statistical analyses were processed
using SAS v.9.2.
AER-045/048
Agreement between the first valid FeNO mea-
surements from the two devices was confirmed
if the lower limit of the one-sided 95% CI of the
proportion of patients within the tolerance
limits was C0.90. Differences of \10 ppb for
absolute values\50 ppb and of\20% for those
[50 ppb were considered within tolerance lim-
its. A clinically significant change in FeNO is
considered to be[10 ppb (or 20%) [9], so device
differences within these limits were considered
clinically non-significant. Normal approxima-
tion was used to calculate the CI when the
observed proportion (p) and 1 - p was[5/n [15],
otherwise the exact CI was calculated.
Agreement was also analyzed between first
valid FeNO measurements from the two devices
and evaluation of the mean differences between
mean values from each device using
Bland–Altman plots. Intra-individual values and
mean values of FeNO measurements from each
device were evaluated using 95% limits of
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agreement, Weighted Deming Regression anal-
ysis, and scatter plots with regression lines.
Repeatability was assessed by analyzing the
differences between mean intra-subject stan-
dard deviation (SD) of duplicate FeNO mea-
surements from each device using the Wilcoxon
Signed Rank Test.
TV-014/018
Repeatability was measured using NIOX VERO
when three consecutive valid FeNO measure-
ments were obtained from one subject by three
different operators using the same device;
assessment was based on NCCLS EP5-A2 guid-
ance [16]. Intra-subject variation was obtained
for each subject and the coefficient of variance
(CV) was calculated. The intra-subject variance,
CV and upper one-sided 95% CI were generated
for each measure. Summaries were provided for
subjects with mean FeNO \50 ppb and those
with mean FeNO C50 ppb. In TV-018, enroll-
ment was stratified for subjects with FeNO
[40 ppb based on their first FeNO value.
Details of additional analyses and any
changes in the planned analyses are provided in
the online supplement.
Analysis Populations
In AER-045/048, efficacy analyses were per-
formed using subjects with C1 valid measure-
ment using NIOX MINO and NIOX VERO
(Efficacy Subjects population) and the All Sub-
jects population was used for all other analyses.
In TV-014/018, subjects completing three FeNO
measurements were included in the Efficacy
Subjects population.
Sample Size
Ninety evaluable subjects were planned to give
[80% power to demonstrate that the lower
limit of a 90% CI was C0.90. This was based on
the hypothesis that the true proportion within
tolerance limits was 0.97 (AER-045), with an
extra 20–30 subjects planned and stratified by
baseline FeNO level to give 10 subjects with
FeNO [40 and \50 ppb, and 10–20 subjects
with FeNO C50 ppb (AER-048).
Between 80 and 90 subjects were planned,
based on the expected precision for the
estimated intra-subject variance for subjects
with valid FeNO values to obtain approximately
20 subjects with FeNO values C50 ppb (TV-014);
a minimum sample size of 20 was planned given
the one-sided upper bound of the SD was 1.18
in order to establish relative variance estimates
for subjects with FeNO[40 ppb (TV-018).
Approximately 40 operators were planned
with the number of operators per site based on
the number of planned subjects. Each set of 3
operators was allowed to make only one
assessment together, no pair of operators con-
ducted more than three assessments together,




Subject demographics are presented in Table 1.
Of the 112 subjects enrolled, 8 (7.1%) did not
complete the AER045/048 studies: 4 (3.6%) did
not complete the two approved exhalations
using NIOX VERO within the maximum
number of attempts allowed; 1 (0.9%) experi-
enced NIOX VERO instrument failure; and 3
(2.7%) had a FeNO concentration \5 ppb. All
subjects completed the TV-014/018 studies.
In TV-014/018, 54 operators were employed,
all female, with a mean (SD) age of 48.5 (13.85)
years with the largest proportion trained as
registered nurses (46.3%), or as licensed practi-
cal nurses/associated nursing degree (20.4%)
(Supplementary Table 1).
No AEs, serious injuries, issues or problems
were reported with use of either device.




The primary objective of the study, showing
that the 95% CI for the proportion of subjec-
tions within the tolerance limits was above
0.90, was not met when comparing NIOX
MINO and NIOX VERO (Table 2). The mean
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overall observed paired difference (SD) between
the devices in relation to the mean first valid
FeNO was -4.6 (6.45) ppb equating to a mean
percent difference of -13.2% (33.95). The mean
observed paired difference in average results
(NIOX VERO – NIOX MINO) was -4.6 ppb
(95% CI -5.825 to -3.377; p\0.0001) (Fig. 1).
The slope of the Weighted Deming Regression
Analysis plot of first valid FeNO values was
0.842 (95% CI 0.757, 0.927) with a y-intercept
of -0.472 ppb (95% CI -1.999, 1.055) (Fig. 2).
Evaluation of the mean differences in mean
FeNO values obtained from each device gave a
mean observed difference in average results
(NIOX VERO – NIOX MINO) of -4.5 ppb
(95% CI -5.635 to -3.449; p\0.0001). Similar
results were seen with the mean of the average
FeNO measurement on each device: the
Weighted Deming Regression analysis slope was
0.929 (95% CI 0.854, 1.033) and y-intercept was
-2.418 ppb (95% CI -3.861, -0.974). FeNO
measurements using NIOX VERO were slightly
lower than those using NIOX MINO by
approximately 3 ppb, which remained within
the technical specifications of the devices
(±5 ppb).
Reproducibility
Intra-subject repeatability was demonstrated for
both devices, with significantly better repeata-
bility achieved with NIOX VERO than NIOX
MINO (median 0.25 vs, 1.00, respectively;
p = 0.0112) (Table 3).
Inter-operator Repeatability
Inter-operator repeatability was achieved using
the NIOX VERO. Pooled mean intra-subject
variance was 6.61 ± 17.954 ppb (upper 95% CI
Table 1 Demographics, pooled for studies AER-045 and AER-048 and for studies TV-014 and TV-018
AER-045/048 TV-014/018
Number of subjects enrolled 112 122
Number of subjects randomized to MINO:VERO device sequence 56 (50) NA
Mean age (SD), years 28.7 (18.56) 34.3 (17.91)
Sex, n (%), male 54 (48.2) 53 (43.4)
Asthma, n (%) 112 (100) 64 (52.5)
Efﬁcacy subjects
# with 1 valid FeNO measurement on each device, n (%) 109 (97.3) NA
# with 2 valid FeNO measurements on each device, n (%) 107 (95.5) NA
FeNO fractional exhaled nitric oxide, SD standard deviation, NA not applicable
Table 2 Summary of the number and proportion of subjects within the tolerance limits for ﬁrst valid and mean FeNO
measurement; pooled data for studies AER-045 and AER-048 (Efﬁcacy Subjects)
AER-045/048
First valid FeNO measurement Mean FeNO measurement
Number of subjects in analysis 109 109
Number with tolerance limits 99 98
Proportion within tolerance limits 0.908 0.899
Lower limit of a 95% CI 0.838 0.827
CI conﬁdence interval, FeNO fractional exhaled nitric oxide
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9.41) with an estimated SD of 2.57 (upper 95%
CI 3.07). The CV was 0.066 ± 0.054 (upper 95%
CI 0.074) (Fig. 3a, b; Supplementary Table 2).
There was no observed operator-order effect
on the FeNO results. Post hoc repeated analysis
of variance (ANOVA) showed mean FeNO
Fig. 1 Bland Altman Plot results for the ﬁrst valid FeNO measurement on each device (NIOX VERO and NIOX
MINO showing pooled study data from studies AER-045 and AER-048 (Efﬁcacy Subjects)
Fig. 2 Observed results for ﬁrst valid FeNO measurement on both devices (NIOX VEROand NIOX MINO) for
pooled study results from study AER-045 and AER-048 (Efﬁcacy Subjects)
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values were similar between all three operators,
but, due to the large sample size, small but sta-
tistically significant differences were noted
(p\0.05) (Table 4; Supplementary Fig. 1a–c).
Post hoc Weighted Deming Regression on
the three pairs of observations gave an esti-
mated bias\2% for all pairs (estimated percent
bias close to 1%; estimated average bias between
-1.00 and 1.20% depending on the pairs
assessed).
Categorical FeNO values were consistent and
repeatable for all subjects. For FeNO \50 ppb,
mean intra-subject variance was 1.37 ± 2.136
(upper 95% CI 1.77), with an estimated SD of
1.17 (upper 95% CI 1.33) and CV of
0.072 ± 0.058 (upper 95% CI 0.082). For FeNO
C50 ppb, mean intra-subject variance was
21.97 ± 30.976 (upper 95% CI 31.64), with an
estimated SD of 4.69 (upper 95% CI 5.62) and
CV of 0.048 ± 0.036 (upper 95% CI 0.060).
DISCUSSION
In our studies, FeNO values were obtained using
two electrochemical exhaled NO analyzers,
NIOX MINO and NIOX VERO. The subject
population included adults and children with
asthma and was representative of asthma
patients in the US and EU [17]. These were the
first studies to compare NIOX VERO with
NIOX MINO and showed a clinically accept-
able agreement between the devices with a sig-
nificant improvement in reproducibility with
NIOX VERO compared to the reference device.
While there was a statistically significant dif-
ference between the two analyzers, the differ-
ences were small and are unlikely to be of
clinical significance in the care of patients. The
same agreement was seen when comparing the
first valid measurement and the mean of two
measurements. Although FeNO measurements
using the NIOX VERO were slightly lower than
those using the NIOX MINO (by approxi-
mately 3 ppb) they were highly correlated and
the difference was within the technical specifi-
cation of the instrument (±5 ppb).
To date, NIOX MINO has been compared
with three chemiluminescence NO analyzers,
the NIOX, Ecomedics and Sievers NOA280i
[18–30]. All these studies showed agreement
between the FeNO values obtained with the
devices being studied, with a clinically accept-
able level of agreement shown with NIOX
[19–22, 25, 26] and Ecomedics [29]. NICE have
also reviewed evidence from studies comparing
NIOX MINO and NIOX VERO with chemi-
luminescence analyzers to establish whether
these devices could be considered equivalent
[31]. Some differences were observed, and
equivalence seemed poorer under certain cir-
cumstances, such as in patients with higher
FeNO levels. However, there was generally a
good correlation seen for NIOX VERO and
NIOX MINO with other chemiluminescence
analyzers so that these devices are considered
broadly equivalent [31].
Intra-subject repeatability was acceptable for
both devices with significantly better repeata-
bility shown for NIOX VERO than NIOX
MINO. FeNO measurements using NIOX
VERO were reproducible, consistent and well
within the technical specifications of the
device. Our findings correlate with previous
observations with NIOX MINO; other studies
in adults and children have reported excellent
reproducibility when using this device
[11, 21, 22, 25, 29, 30, 32, 33]. However, poor
Table 3 Intra-subject variance for efﬁcacy subjects with two valid FeNO measurements on each device to show repeatability
(Efﬁcacy Subjects)
Intra-subject variance NIOX VERO NIOX MINO Paired differences
Mean (SD) 4.79 (23.701) 4.87 (9.292) -0.08 (25.166)
Median 0.25 1.00 -0.025




reproducibility was seen in one study of NIOX
MINO specifically in children and teenagers,
but only when comparing absolute FeNO val-
ues—reproducibility was acceptable when FeNO
values were categorized as low, normal, inter-
mediate or high [19].
Our findings showed no observable pattern
of a training effect or order effect on FeNO
results when measured three times using NIOX
VERO by three different operators. These
results support the feasibility of using NIOX
VERO at the point of care and are consistent
with those seen using NIOX MINO. Gill et al.
[11] showed close agreement between replicate
operator measures for NIOX MINO; mean
within-subject SD in 17 subjects with FeNO
\30 ppb was 1.15 (95% CI 0.67–1.53) which
was below the set limit of 3 ppb. In the three
subjects with FeNO [30 ppb, the mean
within-subject coefficient of variation was 2.4
and below the hypothesis limit of 10 [11].
How did higher FeNO affect our results? In
TV-014/018, increased variability between
measurements was seen as the average subject
FeNO value increased, but the CV appeared to
remain relatively constant across the range of
measured values. Furthermore, values were
consistently within 20% of their overall mean
and all pairs were within 10 ppb for values with
an overall mean\50 ppb. With regards to sta-
tistical considerations, there was no evidence of
bias across the three operator assessments as
confirmed by Weighted Deming Regression and
ANOVA. Variability did increase in time and a
few pairs of high values differed by [20%,
although in these cases it would not have
affected the C50 ppb assessment, and the CV
was similar among the data cuts considered.
Further, across all studies, NIOX MINO and
NIOX VERO were shown to be safe in subjects
with high FeNO.
Table 4 FeNO results by operator order and site by mean subject FeNO value for pooled study data from studies TV-014
and TV-018 (Efﬁcacy Subjects)
Operator (1) All observations ANOVA p value
1st operator 2nd operator 3rd operator
Subjects with FeNO\50 ppb
n 91 91 91 273 0.9979
Mean (SD) 15.0 (10.44) 15.1 (10.77) 15.0 (10.99) 15.0 (10.70)
Median 12.0 11.0 10.0 11.0
Min, max 5, 47 5, 47 5, 50 5, 50
Subjects with FeNO C50 ppb
n 31 31 31 93 0.8006
Mean (SD) 76.5 (28.35) 80.6 (29.34) 81.0 (30.52) 79.4 (29.17)
Median 69.0 72.0 72.0 71.0
Min, max 49, 163 52, 174 49, 173 49, 174
ANOVA analysis of variance, FeNO fractional exhaled nitric oxide, max maximum, min minimum, SD standard deviation
bFig. 3 a Individual FeNO measurements versus subject
mean FeNO for pooled study data from studies TV-014
and TV-018; b individual FeNO measurements: subject
mean FeNO for pooled study data from studies TV-014
and TV-018 (Efﬁcacy Subjects). Both ﬁgures provide
evidence for inter-operator repeatability using NIOX
VERO
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Study Strengths and Limitations
These were one-visit studies that were simply
designed in order to evaluate technical valida-
tion of the devices. More visits over time would
have demonstrated how NIOX VERO can
measure changes due to both inter-operator and
biological variability.
CONCLUSION
Our findings have shown that the NIOXMINO
and new NIOX VERO analyzers are clinically
equivalent when used in an asthma population
representative of that seen in the US and EU.
Furthermore, we have shown that FeNO mea-
surements taken using the NIOX VERO ana-
lyzer are reproducible, consistent and well
within the technical specifications of the
device, showing no observable pattern of a
training effect or operator-order effect on FeNO
results. Thus, our findings validate the
portable NIOX VERO, enabling its clinical use
in both children and adults.
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